<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888173</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0229I</org_study_id>
    <secondary_id>NCI-2011-01918</secondary_id>
    <secondary_id>CA182-029</secondary_id>
    <secondary_id>CDR0000641191</secondary_id>
    <secondary_id>GOG-0229I</secondary_id>
    <secondary_id>GOG-0229I</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00888173</nct_id>
  </id_info>
  <brief_title>Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer</brief_title>
  <official_title>A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well brivanib alaninate works in treating patients with
      endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
      blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the activity of brivanib (brivanib alaninate) for patients with recurrent or
      persistent endometrial cancer with the frequency of patients who survive progression-free for
      at least 6 months after initiating therapy or have objective tumor response..

      SECONDARY OBJECTIVES:

      I. To determine the duration of progression-free survival and overall survival. II. To
      determine the nature and degree of toxicity of brivanib as assessed by Common Terminology
      Criteria for Adverse Events (CTCAE) version (v)3.0 in this cohort of patients.

      TERTIARY OBJECTIVES:

      I. To determine whether activating mutations in fibroblast growth factor receptor 2 (FGFR2)
      are associated with progression-free survival status &gt; 6 months following brivanib treatment,
      objective tumor response following brivanib treatment, or endometrioid histology.

      II. To explore the associations between select biomarkers and response to brivanib
      (progression-free survival status &gt; 6 months and objective tumor response), measures of
      clinical outcome (progression-free survival and overall survival) or disease status including
      histologic cell type: i) mutations in FGFR2 or phosphatase and tensin homolog (PTEN) in
      deoxyribonucleic acid (DNA) from formalin-fixed and paraffin-embedded (FFPE) tumor or normal
      blood cells; ii) immunohistochemical (IHC) expression of the FGFR family and ligands, steroid
      receptor isoforms or phosphorylated (p) v-akt murine thymoma viral oncogene homolog 1 (AKT)
      in FFPE tumor; iii) concentration or the change in the concentration of vascular endothelial
      growth factor (VEGF) or type IV collagen in pre-cycle 1, pre-cycle 2 and/or pre-cycle 3
      plasma.

      III. To explore the relationship among the panel of biomarkers evaluated in this cohort: i)
      mutations in FGFR2 or PTEN; ii) IHC expression of the FGFR family and ligands, steroid
      receptor isoforms or pAKT; iii) concentration or the change in the concentration of VEGF or
      type IV collagen.

      OUTLINE:

      Patients receive brivanib alaninate orally (PO) once daily (QD) on days 1-28. Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years and
      then every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2009</start_date>
  <completion_date type="Actual">July 16, 2016</completion_date>
  <primary_completion_date type="Actual">July 16, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival &gt; 6 Months</measure>
    <time_frame>For patients whose disease can be evaluated by physical examination, progression was assessed prior to each cycle for 6 months.</time_frame>
    <description>Whether or not the patient survived progression-free for at least 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>If evaluated by physical exam, response was assessed prior to each cycle. If evaluated by CT or MRI, response was assessed during course of therapy. Overall time frame is up to 6 months.</time_frame>
    <description>Per response evaluation criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;= 30 % decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR+PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Survival</measure>
    <time_frame>From entry into the study to death or the date of last contact, assessed up to 5 years</time_frame>
    <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on overall survival will be examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Progression-free Survival</measure>
    <time_frame>Form study entry until disease progression, death or date of last contact, assessed up to 5 years</time_frame>
    <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on progression-free survival will be examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events as Assessed by CTCAE v3.0 Criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Adverse Events (grade 3 or higher)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Activating Mutation in FGFR2</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be correlated with clinical measures of outcome such as tumor response, progression-free survival (PFS), and endometrioid histology.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Concentration of VEGF and Type IV Collagen</measure>
    <time_frame>Baseline to up to pre-course 3</time_frame>
    <description>Will be correlated with PFS, OS, tumor response, and histologic cell type.</description>
  </other_outcome>
  <other_outcome>
    <measure>IHC Expression of FGFR Family and Ligands, Steroid Receptor Isoforms, and pAKT</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be correlated with PFS, OS, tumor response, and histologic cell type.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutations in FGFR2 and PTEN</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be correlated with PFS, overall survival (OS), tumor response, and histologic cell type.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Endometrial Adenocarcinoma</condition>
  <condition>Endometrial Clear Cell Adenocarcinoma</condition>
  <condition>Endometrial Mixed Adenocarcinoma</condition>
  <condition>Endometrial Mucinous Adenocarcinoma</condition>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Endometrial Squamous Cell Carcinoma</condition>
  <condition>Endometrial Transitional Cell Carcinoma</condition>
  <condition>Endometrial Undifferentiated Carcinoma</condition>
  <condition>Recurrent Uterine Corpus Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (brivanib alaninate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivanib Alaninate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (brivanib alaninate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (brivanib alaninate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have recurrent or persistent endometrial carcinoma, which is refractory
             to curative therapy or established treatments; histologic confirmation of the original
             primary tumor is required

               -  Patients with the following histologic epithelial cell types are eligible:
                  endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma,
                  clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not
                  otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell, and
                  transitional cell carcinoma

          -  All patients must have measurable disease; measurable disease is defined as at least
             one lesion that can be accurately measured in at least one dimension (longest
             dimension to be recorded); each lesion must be &gt;= 20 mm when measured by conventional
             techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic
             resonance imaging (MRI), or &gt;= 10 mm when measured by spiral CT

          -  Patients must have at least one ?target lesion? to be used to assess response on this
             protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST); tumors
             within a previously irradiated field will be designated as ?non-target? lesions unless
             progression is documented or a biopsy is obtained to confirm persistence at least 90
             days following completion of radiation therapy

          -  Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
             protocol, if one exists; in general, this would refer to any active GOG Phase III or
             Rare Tumor protocol for the same patient population

          -  Patients who have received one prior regimen must have a GOG performance status of 0,
             1, or 2; patients who have received two prior regimens must have a GOG performance
             status of 0 or 1

          -  Recovery from effects of recent surgery, radiotherapy, or chemotherapy

          -  Patients should be free of active infection requiring antibiotics (with the exception
             of uncomplicated urinary tract infection [UTI])

          -  Any hormonal therapy directed at the malignant tumor must be discontinued at least one
             week prior to registration

          -  Any other prior therapy directed at the malignant tumor, including immunologic agents,
             must be discontinued at least three weeks prior to registration

          -  Patients must have had one prior chemotherapeutic regimen for management of
             endometrial carcinoma; chemotherapy administered in conjunction with primary radiation
             as a radio-sensitizer will be counted as a systemic chemotherapy regimen

          -  Patients are allowed to receive, but are not required to receive, one additional
             cytotoxic regimen for management of recurrent or persistent endometrial disease
             according to the following definition:

               -  Cytotoxic regimens include any agent that targets the genetic and/or mitotic
                  apparatus of dividing cells, resulting in dose-limiting toxicity to the bone
                  marrow and/or gastrointestinal mucosa

               -  Note: Patients on this non-cytotoxic study are allowed to receive one additional
                  cytotoxic chemotherapy regimen for management of recurrent or persistent
                  endometrial disease, as defined above; however, patients are encouraged to enroll
                  on second-line non-cytotoxic studies prior to receiving additional cytotoxic
                  therapy

          -  Patients must NOT have received any non-cytotoxic therapy for management of
             endometrial cancer with the exception of hormonal therapy

          -  Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to
             Common Terminology Criteria (CTCAE v3.0) grade 1

          -  Platelets greater than or equal to 100,000/mcl

          -  Hemoglobin &gt; 9 g/dl

          -  Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE
             v3.0 grade 1

          -  Urinalysis needs to be assessed at baseline and proteinuria must be less than or equal
             to 3+ by dipstick (CTCAE v3.0 grade 2 or less); if the urine dipstick is &gt; 3+, a
             24-hour protein level can be done, as clinically indicated by the investigator; the
             24-hour protein level must be less than or equal to 3.5 g/24 hours (CTCAE v3.0 grade 2
             or less)

          -  Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less
             than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)

          -  Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)

          -  Albumin greater than or equal to 2.5 g/dl

          -  Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1

          -  Prothrombin time (PT) such that international normalized ratio (INR) is &lt; 1.5 x ULN;
             patients on therapeutic warfarin are excluded from trial, anticoagulation with low
             molecular weight heparin is allowed

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Patients must meet pre-entry requirements

          -  Patients of childbearing potential must have a negative serum pregnancy test performed
             48 hours prior to study entry and be practicing an effective form of contraception
             during the study and for at least 3 months after receiving the final treatment of
             brivanib

          -  All patients must have a baseline electrocardiogram completed prior to study entry;
             baseline electrocardiogram (ECG) should be repeated if corrected QT interval (QTc) is
             found to be &gt; 450 msec; QTc must NOT be &gt; 450 msec on both ECGs performed during the
             same visit

        Exclusion Criteria:

          -  Patients who have had prior therapy with brivanib or anti-vascular, anti-PDGFR
             (platelet-derived growth factor receptor) or anti-FGFR (fibroblast growth factor
             receptor) therapy

          -  Patients with a history of other invasive malignancies, with the exception of
             non-melanoma skin cancer and other specific malignancies as noted below, are excluded
             if there is any evidence of the other malignancy being present within the last three
             years; patients are also excluded if their previous cancer treatment contraindicates
             this protocol therapy

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis OTHER THAN for the treatment of endometrial cancer within the last three
             years are excluded; prior radiation for localized cancer of the breast, head and neck,
             or skin is permitted, provided that it was completed more than three years prior to
             registration, and the patient remains free of recurrent or metastatic disease

          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
             THAN for the treatment of endometrial cancer within the last three years are excluded;
             patients may have received prior adjuvant chemotherapy for localized breast cancer,
             provided that it was completed more than three years prior to registration, and that
             the patient remains free of recurrent or metastatic disease

          -  Patients that are on required chronic anti-platelet therapy (aspirin &gt; 300 mg/day, or
             clopidogrel greater than or equal to 75 mg/day)

          -  Patients with gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE
             grade &gt;= 3 within 30 days prior to study entry

          -  Patients with a history of poor wound healing, non healing ulcers or bone fractures
             within the last 3 months

          -  Patients with uncontrolled or significant cardiovascular disease including:

               -  Myocardial infarction within 12 months

               -  Uncontrolled angina within 12 months

               -  Class III-IV New York Heart Association (NYHA) congestive heart failure

               -  Uncontrolled hypertension (systolic blood pressure [BP] &gt; 150 or diastolic BP &gt;
                  100 mmHg for 24 hours) despite optimized anti-hypertensive therapy; BP must be
                  below 150/100 mmHg at screening; subjects with a history of hypertension who are
                  receiving treatment with calcium channel blockers that are cytochrome P450 family
                  3, subfamily A, polypeptide 4 (CYP3A4) inhibitors should be changed to an
                  alternative antihypertensive medication before study entry

               -  History of stroke, transient ischemic attack (TIA), or other central nervous
                  system (CNS) ischemic event

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
                  digoxin

               -  Patients must have pre-therapy left ventricle ejection fraction (LVEF) testing
                  and have an ejection fraction &gt; 50%

               -  Patients with valvular heart disease &gt;= CTCAE grade2

          -  Patients with a serious uncontrolled medical disorder or active infection which would
             impair the ability of the subject to receive protocol therapy or whose control may be
             jeopardized by the complications of this therapy

          -  Pre-existing thyroid abnormality with thyroid function that can not be maintained in
             the normal range with medication

          -  Patients with hyponatremia (sodium &lt; 130 mEq/L)

          -  Patients with active/known human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C

          -  Patients with known brain metastases

          -  Patients who are pregnant or nursing

          -  Patients with inability to swallow tablets or untreated malabsorption syndrome

          -  Baseline serum potassium &lt; 3.5 mmol/L (potassium supplementation may be given to
             restore the serum potassium above this level prior to entry study)

          -  Patients on therapeutic warfarin anticoagulation will be excluded; patients converted
             to anticoagulation with a heparin compound will be allowed provided the patient?s PT
             is such that international normalized ratio (INR) is =&lt; 1.5 x ULN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Powell</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-William R Bliss Cancer Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa-Wide Oncology Research Coalition NCORP</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Laurel</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Lutheran Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System/Center for Advanced Medicine</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute-Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Gynecological Oncology</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Gynecology Specialists</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology at Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301-3526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology Limited at Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>November 28, 2016</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was activated on 7/6/2009 and suspended to accrual on 12/14/2009. The study reopened on 9/7/2010 and closed on 1/3/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Brivanib</title>
          <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Wrong Primary</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible: required test not done</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brivanib</title>
          <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival &gt; 6 Months</title>
        <description>Whether or not the patient survived progression-free for at least 6 months.</description>
        <time_frame>For patients whose disease can be evaluated by physical examination, progression was assessed prior to each cycle for 6 months.</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Brivanib</title>
            <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival &gt; 6 Months</title>
          <description>Whether or not the patient survived progression-free for at least 6 months.</description>
          <population>Eligible and Treated Patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="19" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Per response evaluation criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;= 30 % decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR+PR.</description>
        <time_frame>If evaluated by physical exam, response was assessed prior to each cycle. If evaluated by CT or MRI, response was assessed during course of therapy. Overall time frame is up to 6 months.</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Brivanib</title>
            <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Per response evaluation criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;= 30 % decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR+PR.</description>
          <population>Eligible and Treated Patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="9" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Survival</title>
        <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on overall survival will be examined.</description>
        <time_frame>From entry into the study to death or the date of last contact, assessed up to 5 years</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Brivanib</title>
            <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Survival</title>
          <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on overall survival will be examined.</description>
          <population>Eligible and Treated Patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="9.2" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Progression-free Survival</title>
        <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on progression-free survival will be examined.</description>
        <time_frame>Form study entry until disease progression, death or date of last contact, assessed up to 5 years</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Brivanib</title>
            <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Progression-free Survival</title>
          <description>Characterized graphically with Kaplan-Meier estimates and using descriptive statistics. The effect of cell type (type I versus type II endometrial cancers) on progression-free survival will be examined.</description>
          <population>Eligible and Treated Patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.0" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Adverse Events as Assessed by CTCAE v3.0 Criteria</title>
        <description>Adverse Events (grade 3 or higher)</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Eligible and Treated Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Brivanib</title>
            <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Adverse Events as Assessed by CTCAE v3.0 Criteria</title>
          <description>Adverse Events (grade 3 or higher)</description>
          <population>Eligible and Treated Patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constitutional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary/Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphatics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death, Not CTC coded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Activating Mutation in FGFR2</title>
        <description>Will be correlated with clinical measures of outcome such as tumor response, progression-free survival (PFS), and endometrioid histology.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Concentration of VEGF and Type IV Collagen</title>
        <description>Will be correlated with PFS, OS, tumor response, and histologic cell type.</description>
        <time_frame>Baseline to up to pre-course 3</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>IHC Expression of FGFR Family and Ligands, Steroid Receptor Isoforms, and pAKT</title>
        <description>Will be correlated with PFS, OS, tumor response, and histologic cell type.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mutations in FGFR2 and PTEN</title>
        <description>Will be correlated with PFS, overall survival (OS), tumor response, and histologic cell type.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events (SAEs) considered to be treatment related for up to 5 years after stopping study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brivanib</title>
          <description>Brivanib 800 mg orally every day (one cycle = 28 days) until disease progression or adverse effects prohibit further therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Obstruction, Gi - Small Bowel Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death No Ctcae Term - Disease Progression Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Death No Ctcae Term - Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/St: Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Whole Body/Generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, Gu - Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Inr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia - Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lt Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Middle Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Otitis External Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hearing (Without Monitoring Program)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Flashing Lights/Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dental: Teeth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Incontinence, Anal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Sympt) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam) - Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Chest /Thorax Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Chest Wall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Throat/Pharynx/Larynx</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Joint</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Abdominal Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Middle Ear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: External Ear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Muscle</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain: Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Catheter-Related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Sinus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Urinary Tract Nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Upper Airway Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Sinus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf Unknown Anc: Urinary Tract Nos</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Gr 3 Or 4 Anc: Bone (Osteomyelitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: Bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Inf W/Nml Or Gr 1 Or 2 Anc: External Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ast</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gfr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Alt</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bicarbonate, Serum-Low</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/St: Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Whole Body/Generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle Weakness - Extremity-Lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Euphoria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neuropathy,cranial - Cn Xii Motor-Tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neuropathy-Motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation, Gu - Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal/Paranasal Reactions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hair Loss/Alopecia (Scalp Or Body)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hand-Foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Inr</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ptt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Urinary Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gu - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Gi - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Pulmonary - Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Gedeon For Michael Sill, PhD.</name_or_title>
      <organization>NRG Oncology</organization>
      <phone>716-845-1169</phone>
      <email>lgedeon@gogstats.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

